Navigation Links
Clinical Tests Demonstrate Long-Term Effectiveness of Oral Glutathione Supplements - Kyowa Study
Date:5/7/2013

NEW YORK, May 7, 2013 /PRNewswire-iReach/ -- Glutathione is the body's master antioxidant involved in protecting cells and tissues from oxidants and a large variety of other toxins and insults. Debate over whether orally administered glutathione could be effective at enhancing glutathione levels in cells and tissues has simmered for years. Now, a Penn State College of Medicine study shows oral supplementation is effective in increasing the body's stores of this vital nutrient.

(Logo: http://photos.prnewswire.com/prnh/20130507/CG09410)

The study of 54 healthy adults revealed that glutathione (GSH) levels of those taking 1000mg of Setria® Glutathione a day for six months increased 30%-35% in many compartments including red blood cells, lymphocytes and plasma, and of those taking 250mg of Setria® Glutathione increased in whole blood. And as glutathione stores increased in the high-dose group, so did the function of natural killer (NK) cells, a marker for increased immune defense, said John P. Richie, Jr. , Ph.D., professor of Public Health Sciences and Pharmacology at Penn State College of Medicine.

"A battery of immune function markers was examined after three months of glutathione supplementation and NK cytotoxicity was enhanced more than two-fold for participants taking 1000mg daily doses," Dr. Richie said. "We believe GSH supplementation may represent an effective intervention strategy for disease prevention and may enhance immune function."

There is a school of thought that contends that glutathione is broken down in the stomach and intestine and effective increases of GSH must come via intravenous administration. However, previous animal studies showed that orally administered glutathione is bioavailable and will enhance tissue GSH levels, Dr. Richie said.

"Our research showed that in most cases increases were dose and time dependent, and levels returned to baseline after a one-month washout," he said. "By taking daily GSH supplements, we believe efficacious levels will persist, and that oral intake is an effective means of chronically enhancing the body's stores."

Dr. Richie presented the study findings – "Enhanced Glutathione Levels in Blood and Buccal Cells by Oral Glutathione Supplementation" – at the Experimental Biology 2013 conference in Boston on April 22. The study was a joint effort of the Pennsylvania Department of Public Health Sciences, the Penn State Hershey Cancer Institute, and the Penn State College of Medicine.

About John P. Richie , Ph.D.

Dr. Richie is professor, Public Health Sciences and Pharmacology, at Penn State College of Medicine, State College, Penn. He has researched has researched glutathione for more than 30 years, including its role in protecting against oxidative damage during aging and the development of cancer at numerous sites in the body. Dr. Richie's research focuses on the factors that regulate glutathione, oxidative stress and cancer risk in individuals and in various populations.

About Setria

Setria® Glutathione, manufactured by Kyowa Hakko USA, is a clinically studied, absorbable form of glutathione that can help replenish the body's reserves that may be depleted as a result of poor lifestyle choices, stress, or natural aging. Called the "master antioxidant," benefits of glutathione include protecting cells in the body from the damaging effects of oxidative stress and toxins. Setria Glutathione is manufactured through a patented fermentation and patent pending for increasing NK natural killer (NK) cells, is pure, vegetarian and allergen-free. For more information about Setria GSH, please visit: http://www.setriaglutathione.com.

About Kyowa Hakko USA

Kyowa Hakko USA is the North American sales office for Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing and marketing of pharmaceuticals, nutraceuticals and food products. Kyowa is the maker of branded ingredients including Cognizin® Citicoline, Lumistor® L-Hydroxyproline, Pantesin® Pantethine, Setria® Glutathione, as well as Sustamine™ L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

Media Contact:

Dave Clifton , Setria® Glutathione, 385-222-7035, dave@brandhive.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Setria
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
2. Federal Government Organization achieves cleaner and faster Clinical Study Data using Tablet PCs from TabletKiosk
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. NYSCF scientists develop new protocol to ready induced pluripotent stem cell clinical application
5. ACMG releases report on incidental findings in clinical exome and genome sequencing
6. IUPUI stem cell research could expand clinical use of regenerative human cells
7. New AAN/ALS Association Clinical Fellow Will Pursue Immune Biomarkers
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
10. Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments
11. Hot topics in translational bone research at IOF-ESCEO 3rd Pre-Clinical Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... , ... February 28, 2017 , ... ... most advanced manufacturing technology for use in filling injectable drug products into vials, ... Vanrx Pharmasystems SA25 robotic work-cell . CEO of Singota Solutions Alisa Wright expressed ...
(Date:2/28/2017)... Feb. 28, 2017  Phosphorus, a computational genomics ... formation of the Phosphorus Scientific Advisory Board, an ... to advise the company on the development of ... initiatives. Please visit http://phosphorus.com/about-us/ to learn ... "We,ve gathered some of the top leaders ...
(Date:2/28/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... company, today announced that its Lab Testing Division(LTD),s ... once again passed US FDA,s bioequivalence (BE) inspection ... from FDA thoroughly audited WuXi,s quality system during ... operation infrastructure, equipment, sample storage, archival system, quality ...
(Date:2/28/2017)... CA (PRWEB) , ... February 28, 2017 , ... ACEA ... the treatment of chronic diseases, has announced Dr. Roger (Feng) Luo as the new ... development experience with a number of multinational drug companies, Dr. Luo will now team ...
Breaking Biology Technology: